Analyzing CarePayment Technologies (OTCMKTS:CPYT) and Sera Prognostics (NASDAQ:SERA)
by Renee Jackson · The Cerbat GemSera Prognostics (NASDAQ:SERA – Get Free Report) and CarePayment Technologies (OTCMKTS:CPYT – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.
Institutional & Insider Ownership
54.6% of Sera Prognostics shares are held by institutional investors. 15.8% of Sera Prognostics shares are held by insiders. Comparatively, 13.9% of CarePayment Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Sera Prognostics and CarePayment Technologies”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sera Prognostics | $80,000.00 | 1,693.58 | -$32.90 million | ($0.77) | -4.56 |
| CarePayment Technologies | N/A | N/A | N/A | N/A | N/A |
CarePayment Technologies has lower revenue, but higher earnings than Sera Prognostics.
Profitability
This table compares Sera Prognostics and CarePayment Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sera Prognostics | -34,343.16% | -41.69% | -31.77% |
| CarePayment Technologies | N/A | N/A | N/A |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Sera Prognostics and CarePayment Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sera Prognostics | 1 | 0 | 1 | 0 | 2.00 |
| CarePayment Technologies | 0 | 0 | 0 | 0 | 0.00 |
Sera Prognostics currently has a consensus price target of $5.00, suggesting a potential upside of 42.45%. Given Sera Prognostics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Sera Prognostics is more favorable than CarePayment Technologies.
Summary
Sera Prognostics beats CarePayment Technologies on 6 of the 9 factors compared between the two stocks.
About Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
About CarePayment Technologies
CarePayment Technologies, Inc. provides accounts receivable services in the United States. It offers services for accounts receivables generated by healthcare providers in connection with providing healthcare services to their patients under the CarePayment brand name. The company was formerly known as microHelix, Inc. CarePayment Technologies, Inc. was founded in 1991 and is based in Lake Oswego, Oregon.